Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:PDSB OTCMKTS:RGRX NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/APDSBPDS Biotechnology$1.16+12.1%$0.93$0.51▼$1.92$64.47M1.51805,718 shs712,616 shsRGRXRegeneRx Biopharmaceuticals$0.00$0.00$0.00▼$0.16N/A171.8436 shs186 shsSVRASavara$5.12+0.8%$5.32$1.89▼$7.01$1.05B0.281.51 million shs436,667 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,509.47%PDSBPDS Biotechnology+3.00%-22.56%-20.16%+56.58%-36.81%RGRXRegeneRx Biopharmaceuticals0.00%0.00%0.00%+66.67%+150.00%SVRASavara+7.63%-3.61%-9.45%-11.19%+62.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/APDSBPDS Biotechnology$1.16+12.1%$0.93$0.51▼$1.92$64.47M1.51805,718 shs712,616 shsRGRXRegeneRx Biopharmaceuticals$0.00$0.00$0.00▼$0.16N/A171.8436 shs186 shsSVRASavara$5.12+0.8%$5.32$1.89▼$7.01$1.05B0.281.51 million shs436,667 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,509.47%PDSBPDS Biotechnology+3.00%-22.56%-20.16%+56.58%-36.81%RGRXRegeneRx Biopharmaceuticals0.00%0.00%0.00%+66.67%+150.00%SVRASavara+7.63%-3.61%-9.45%-11.19%+62.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/APDSBPDS Biotechnology 2.33Hold$9.00679.22% UpsideRGRXRegeneRx Biopharmaceuticals 0.00N/AN/AN/ASVRASavara 2.78Moderate Buy$9.1378.15% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, RGRX, PDSB, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026SVRASavara OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.00 ➝ $11.004/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SVRASavara Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.003/16/2026SVRASavara William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.003/16/2026SVRASavara HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29PDSBPDS BiotechnologyN/AN/AN/AN/A$0.07 per shareN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/A$0.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/APDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%N/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%N/ALatest SVRA, RGRX, PDSB, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A5/13/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/A3/13/2026Q4 2025SVRASavara-$0.12-$0.13-$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/APDSBPDS Biotechnology2.732.262.26RGRXRegeneRx BiopharmaceuticalsN/AN/AN/ASVRASavara0.1713.4713.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%PDSBPDS Biotechnology26.84%RGRXRegeneRx BiopharmaceuticalsN/ASVRASavara87.93%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%PDSBPDS Biotechnology9.20%RGRXRegeneRx Biopharmaceuticals12.60%SVRASavara5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionablePDSBPDS Biotechnology2055.82 million50.68 millionOptionableRGRXRegeneRx Biopharmaceuticals3N/AN/ANot OptionableSVRASavara20204.93 million194.07 millionOptionableSVRA, RGRX, PDSB, and ADXS HeadlinesRecent News About These Companies5 Best Penny Stocks to Buy for Long TermMay 21 at 8:36 AM | insidermonkey.comSavara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...May 20 at 9:43 AM | timesargus.comTSavara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026May 20 at 8:15 AM | businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...May 19 at 10:24 PM | uk.finance.yahoo.comSavara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)May 19 at 2:15 PM | businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)May 18 at 2:55 PM | businesswire.comSavara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 16, 2026 | americanbankingnews.comGuggenheim Reaffirms Their Buy Rating on Savara (SVRA)May 15, 2026 | theglobeandmail.comSavara (SVRA) Receives a Buy from Piper SandlerMay 15, 2026 | theglobeandmail.comSavara Reports First Quarter Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceMay 12, 2026 | cadillacnews.comCSwedbank AB Has $5.13 Million Position in Savara Inc. $SVRAMay 10, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRAMay 10, 2026 | marketbeat.comSavara Inc. $SVRA Position Boosted by F m Investments LLCMay 10, 2026 | marketbeat.comSavara (SVRA) to Release Earnings on TuesdayMay 5, 2026 | marketbeat.comAssessing Savara (SVRA) Valuation After FDA Extends Priority Review For MolgramostimApril 26, 2026 | finance.yahoo.comSavara (NASDAQ:SVRA) Coverage Initiated by Analysts at OppenheimerApril 24, 2026 | marketbeat.comSavara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 21, 2026 | marketbeat.comSavara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech SegmentApril 19, 2026 | kalkinemedia.comKAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)April 17, 2026 | theglobeandmail.comSavara Announces New Employment Inducement GrantApril 17, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, RGRX, PDSB, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 05/20/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.PDS Biotechnology NASDAQ:PDSB$1.16 +0.13 (+12.14%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.RegeneRx Biopharmaceuticals OTCMKTS:RGRX$0.0005 0.00 (0.00%) As of 05/20/2026 11:26 AM EasternRegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.Savara NASDAQ:SVRA$5.12 +0.04 (+0.83%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
